Literature DB >> 8557296

Systemic fungal infections: major problems in cancer patients.

R L Powles1, J Mehta.   

Abstract

Over the last decade, with increasing use of aggressive chemotherapy and bone marrow transplantation in the treatment of cancer, fungi have emerged as a major pathogen. The prognosis of established systemic fungal infections remains poor, but newer antifungal drugs such as fluconazole are changing the outlook of therapy and prophylaxis considerably.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8557296

Source DB:  PubMed          Journal:  Indian J Cancer        ISSN: 0019-509X            Impact factor:   1.224


  2 in total

1.  Comparison of a new colorimetric assay with the NCCLS broth microdilution method (M-27A) for antifungal drug MIC determination.

Authors:  R K Li; C M Elie; G E Clayton; M A Ciblak
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  Cost effectiveness of amphotericin B plus G-CSF compared with amphotericin B monotherapy. Treatment of presumed deep-seated fungal infection in neutropenic patients in the UK.

Authors:  T N Flynn; S M Kelsey; D L Hazel; J F Guest
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.